A Phase 3 interventional study of Symbicort (budesonide/formoterol) Turbuhaler and Conventional treatment in Asthma, Bronchial, sponsored by AstraZeneca. Terminated at 52 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.
Among the 359 studies in Asthma by AstraZeneca, this one is the 54th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2006, is one of 121 in phase 3, and was the 48th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in China
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in China
Ages 18–75
AstraZeneca · Sites in United States, Argentina, Czechia and 4 more countries
Ages 4–11
By country, each count listing its studies:
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
359 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 52 · Phase 3 123 · Phase 4 23
First in 1996; this study’s year is marked. 16 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 654 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 175 across the 248 interventional studies, 500 across the 110 observational. Of the 330 that completed or were terminated, 129 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
13 of the studies in Asthma by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
| NCT07218172AstraZenecaCharacterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) | 2026-11-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 359 studies in Asthma by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept. The study will compare the Symbicort Single Inhaler Therapy concept with a conventional stepwise treatment regimen according to the investigator's judgement in patients who present with symptoms on inhaled glucocorticosteroids (GCS) treatment or who require and are already on treatment with a combination of inhaled and long-acting B2 agonists (LABA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug page: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
Time to First Severe Asthma Exacerbation
Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral Glucocorticosteroids (GCS) treatment for at least 3 days.
Time frame: Baseline up to 6 months
Total Number of Severe Exacerbations
Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral (GCS) treatment for at least 3 days.
Time frame: Baseline up to 6 months
Mean Use of as Needed Medication
Mean use of as needed medication during the treatment period
Time frame: Baseline up to 6 months
Use of Inhaled Steroids
Mean micrograms/day of inhaled steroids (beclomethasone dipropionate equivalents)
Time frame: Baseline up to 6 months
Change in the Asthma Control Questionnaire(ACQ) Score
The ACQ is a 7-point scale with scores ranging from 0 (very well controlled) to 6 (very badly controlled)
Time frame: Daily 14 days prior to each of visit 2-4
Peak Expiratory Flow (PEF)
Peak expiratory flow (PEF)
Time frame: 6 months (end of the study)
654
| Milestone | SMART | Conv. Best Practice |
|---|---|---|
| Started | 328 | 326 |
| Completed | 270 | 289 |
| Not completed | 58 | 37 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Withdrawal by subject | 17 | 7 |
| Withdrew: Lost to follow-up | 12 | 8 |
| Withdrew: Protocol violation | 7 | 4 |
| Withdrew: Several reasons | 17 | 15 |
| Withdrew: Incorrect inclusion | 2 | 0 |
| Withdrew: Incorrect randomization | 0 | 1 |
Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral Glucocorticosteroids (GCS) treatment for at least 3 days.
| Days | SMART | Conv. Best Practice |
|---|---|---|
| Time to First Severe Asthma Exacerbation | 174.39 ± 1.76 | 178.97 ± 1.86 |
Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral (GCS) treatment for at least 3 days.
| Exacerbations | SMART | Conv. Best Practice |
|---|---|---|
| Total Number of Severe Exacerbations | 24 | 34 |
Mean use of as needed medication during the treatment period
| Inhalations | SMART | Conv. Best Practice |
|---|---|---|
| Mean Use of as Needed Medication | 1.03 ± 0 | 1.02 ± 0 |
Mean micrograms/day of inhaled steroids (beclomethasone dipropionate equivalents)
| micrograms | SMART | Conv. Best Practice |
|---|---|---|
| Use of Inhaled Steroids | 799 ± 250 | 1184 ± 200 |
The ACQ is a 7-point scale with scores ranging from 0 (very well controlled) to 6 (very badly controlled)
| Scores on a scale | SMART | Conv. Best Practice |
|---|---|---|
| Change in the Asthma Control Questionnaire(ACQ) Score | 0.99 ± 0.0 | 1.08 ± 0.0 |
Peak expiratory flow (PEF)
| L/min | SMART | Conv. Best Practice |
|---|---|---|
| Peak Expiratory Flow (PEF) | 405.9 (110 to 900) | 400.6 (140 to 900) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SMART | — | 10/326 (3.1%) | 0/326 (0%) |
| Conv. Best Practice | — | 5/326 (1.5%) | 0/326 (0%) |
| Event | SMART | Conv. Best Practice |
|---|---|---|
| GastroenteritisGastrointestinal disorders | 1/326 | 0/326 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/326 | 0/326 |
| EpicondylitisMusculoskeletal and connective tissue disorders | 1/326 | 0/326 |
| Gene MutationCongenital, familial and genetic disorders | 1/326 | 0/326 |
| Medullary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/326 | 0/326 |
| Irritable Bowel SyndromeGastrointestinal disorders | 1/326 | 0/326 |
| PneumoniaInfections and infestations | 1/326 | 1/326 |
| DiarrhoeaGastrointestinal disorders | 1/326 | 0/326 |
| Respiratory Tract InfectionInfections and infestations | 1/326 | 0/326 |
| CataractEye disorders | 1/326 | 0/326 |
| Age Continuous(Years) | SMART | Conv. Best Practice | Total |
|---|---|---|---|
| Mean | 43.7 ± 16.4 | 44.3 ± 16.5 | 44.0 ± 16.5 |
| Sex: Female, Male(Participants) | SMART | Conv. Best Practice | Total |
|---|---|---|---|
| Female | 218 | 202 | 420 |
| Male | 110 | 124 | 234 |
The record gives a start of Sep 2006 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol